Listar por autor "Castellano, Daniel"
Mostrando ítems 1-5 de 5
-
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
Castellano, Daniel; Antón-Aparicio, Luis M.; Esteban, Emilio; Sánchez-Hernández, Alfredo; Germá, José Ramón; Batista, Norberto; Maroto, Pablo; Pérez-Valderrama, Begoña; Luque, Raquel; Méndez-Vidal, María José (Taylor & Francis, 2014-07-07)[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel. METHODS: This multi-centre ... -
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
Capdevila, Jaume; Sevilla, Isabel; Alonso, Vicente; Antón-Aparicio, Luis M.; Jiménez Fonseca, Paula; Grande, Enrique; Reina, Juan José; Manzano, José Luis; Alonso Lájara, Juan Domingo; Barriuso, Jorge; Castellano, Daniel; Medina, Javier; López, Carlos; Segura, Ángel; Carrera, Sergio; Crespo, Guillermo; Fuster, José; Munarriz, Javier; García Alfonso, Pilar (BioMed Central, 2015-07-04)[Abstract] Background. Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine ... -
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
Castellano, Daniel; Maroto, José Pablo; Espinosa, Enrique; Grande, Enrique; Bolós Fernández, Victoria; Llinares, Julia; Esteban, Emilio; González del Alba, Aránzazu; Climent, Miguel Ángel; Arranz, José Ángel; Méndez, María José; Fernández Parra, Eva; Antón-Aparicio, Luis M.; Bayona, Cristina; Gallegos, Isabel; Gallardo, Enrique; Samaniego, Luz; García Donas, Jesús (Taylor & Francis, 2017-08-28)[Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate ... -
Expression of sterol regulatory element-binding proteins in epicardial adipose tissue in patients with coronary artery disease and diabetes mellitus: preliminary study
Pérez-Belmonte, Luis M.; Moreno-Santos, Inmaculada; Cabrera-Bueno, Fernando; Sánchez-Espín, Gemma; Castellano, Daniel; Such, Miguel; Crespo-Leiro, María Generosa; Carrasco-Chinchilla, Fernando; Alonso-Pulpón, Luis; López-Garrido, Miguel; Ruiz-Salas, Amalio; Becerra-Muñoz, Víctor M.; Gómez Doblas, Juan José; Teresa Galván, Eduardo de; Jiménez-Navarro, Manuel (Ivyspring, 2017-02-23)[Abstract] Objectives: Sterol regulatory element-binding proteins (SREBP) genes are crucial in lipid biosynthesis and cardiovascular homeostasis. Their expression in epicardial adipose tissue (EAT) and their influence in ... -
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Puente, Javier; Lainez, Nuria; Dueñas, Marta; Méndez-Vidal, María José; Esteban, Emilio; Castellano, Daniel; Martínez-Fernández, Mónica; Basterretxea, Laura; Juan-Fita, María José; Antón-Aparicio, Luis M.; León, Luis; Lambea, Julio; Pérez-Valderrama, Begoña; Vázquez, Sergio; Suárez, Cristina; García del Muro, Xavier; Gallardo, Enrique; Maroto, José Pablo; Samaniego, M. Luz; Suárez-Paniagua, Beatriz; Sanz, Julián; Paramio, Jesús M. (Impact Journals, 2017-03-23)[Abstract] Background: Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further ...